1-7 of 7
Ronald L. Dubowy, MD
Close
Sort by
Journal Articles

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Jennifer R. Brown, MD PhD, Andrew D. Zelenetz, MD PhD, Richard R. Furman, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Marco Montillo, MD, Susan M. O'Brien, MD, Lyndah K. Dreiling, MD, Ronald L. Dubowy, MD, Yeonhee Kim, PhD, Veerendra B. Munugalavada, PhD, Tadeusz Robak, MD PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3016.
https://doi.org/10.1182/blood.V130.Suppl_1.3016.3016
Published: 2017
Journal Articles

Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib

Jennifer R. Brown, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Paolo Ghia, MD PhD, Michael Hallek, MD, Peter Hillmen, MB, ChB, PhD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Ronald L. Dubowy, MD, Barbara Velasco, Christopher C. Waldapfel, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2952.
https://doi.org/10.1182/blood.V126.23.2952.2952
Published: 2015
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2015) 126 (23): 4172.
https://doi.org/10.1182/blood.V126.23.4172.4172
Published: 2015
Journal Articles

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Susan O'Brien, Nicole Lamanna, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Andrew D. Zelenetz, MD PhD, Jan A. Burger, MD PhD, Leanne M. Holes, Yoonjin Cho, PhD, Ronald L. Dubowy, MD, Steven E. Coutre, MD
Journal: Blood
Blood (2014) 124 (21): 1994.
https://doi.org/10.1182/blood.V124.21.1994.1994
Published: 2014
Journal Articles

A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Andrew D. Zelenetz, MD PhD, Nicole Lamanna, MD, Thomas J. Kipps, MD PhD, Steven E. Coutre, MD, Susan O'Brien, Maria Aiello, Yoonjin Cho, PhD, Ronald L. Dubowy, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1986.
https://doi.org/10.1182/blood.V124.21.1986.1986
Published: 2014
Journal Articles

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, MD, PhD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Ronald L. Dubowy, MD, Steven E. Coutre, MD
Journal: Blood
Blood (2013) 122 (21): 2878.
https://doi.org/10.1182/blood.V122.21.2878.2878
Published: 2013
Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Steven E. Coutre, MD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Sven De Vos, MD, PhD, Ian Flinn, MD, PhD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Nina Wagner-Johnston, MD, Don M. Benson, Jr., MD, PhD, Marshall T. Schreeder, MD, Jeff P. Sharman, MD, Thomas Boyd, MD, Stephen Spurgeon, MD, Andrew D. Zelenetz, MD, PhD, Nicole Lamanna, MD, Thomas J. Kipps, MD, PhD, Brad S. Kahl, MD, Celeste M. Bello, MD, Jan A. Burger, MD, PhD, Kanti R. Rai, MD, Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Mirella Lazarov, PhD, Ronald L. Dubowy, MD, Susan M. O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): 1632.
https://doi.org/10.1182/blood.V122.21.1632.1632
Published: 2013